NPR obtained the contract, dated Nov. 17, 2021, through a public records request. Under the deal, the U.S. is paying about $530 for a five-day course of Pfizer’s antiviral, Paxlovid.
Two notable terms of the deal:
1. The contract allows for favored nation pricing, which functions similarly to a retailer’s price match guarantee. If one of six other high-income countries secures a lower price for Paxlovid, the U.S. can ask Pfizer for the same price.
2. There is also a buyback clause in the contract. If Paxlovid’s emergency use authorization is withdrawn for any reason, Pfizer has agreed to buy back unexpired doses of the antiviral pill from the U.S.
“I think this contract reflects a change in the national mood across time,” Robin Feldman, an expert in pharmaceutical law and professor at the University of California Hastings College of the Law in San Francisco, told NPR. “So with vaccines and some treatments on the shelves, the nation is less panicked. U.S. government officials feel less backed into a corner, more able to negotiate.”
View the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
